These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 11454880)

  • 1. High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck.
    Regine WF; Valentino J; Arnold SM; Haydon RC; Sloan D; Kenady D; Strottmann J; Pulmano C; Mohiuddin M
    J Clin Oncol; 2001 Jul; 19(14):3333-9. PubMed ID: 11454880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of concomitant hyperfractionated radiation therapy and double dose intra-arterial cisplatin for squamous cell carcinoma of the head and neck.
    Regine WF; Valentino J; Arnold SM; Sloan D; Kenady D; Strottmann J; Mohiuddin M
    Technol Cancer Res Treat; 2002 Apr; 1(2):133-40. PubMed ID: 12622520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose intra-arterial cisplatin and concurrent hyperfractionated radiation therapy in patients with locally advanced primary squamous cell carcinoma of the head and neck: report of a phase II study.
    Regine WF; Valentino J; John W; Storey G; Sloan D; Kenady D; Patel P; Pulmano C; Arnold SM; Mohiuddin M
    Head Neck; 2000 Sep; 22(6):543-9. PubMed ID: 10941154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck.
    Jeremic B; Milicic B; Dagovic A; Vaskovic Z; Tadic L
    J Clin Oncol; 2004 Sep; 22(17):3540-8. PubMed ID: 15337803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial.
    Jeremic B; Shibamoto Y; Milicic B; Nikolic N; Dagovic A; Aleksandrovic J; Vaskovic Z; Tadic L
    J Clin Oncol; 2000 Apr; 18(7):1458-64. PubMed ID: 10735893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
    Langer CJ; Duffy K; Horwitz EM; Litwin S; Rosvold E; Schol J; Keenan E; Nicolaou N; Friedman CD; Ridge JA
    Cancer Invest; 2006 Mar; 24(2):164-73. PubMed ID: 16537186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
    Ghadjar P; Simcock M; Studer G; Allal AS; Ozsahin M; Bernier J; Töpfer M; Zimmermann F; Betz M; Glanzmann C; Aebersold DM;
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):524-31. PubMed ID: 21300466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
    Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
    Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615.
    Robbins KT; Kumar P; Harris J; McCulloch T; Cmelak A; Sofferman R; Levine P; Weisman R; Wilson W; Weymuller E; Fu K
    J Clin Oncol; 2005 Mar; 23(7):1447-54. PubMed ID: 15735120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results of hyperfractionated radiation and high-dose intraarterial cisplatin for unresectable oropharyngeal carcinoma.
    Spring PM; Valentino J; Arnold SM; Sloan D; Kenady D; Kudrimoti M; Haydon RC; Lee C; Given C; Mohiuddin M; Regine WF
    Cancer; 2005 Oct; 104(8):1765-71. PubMed ID: 16149090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
    Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
    Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.
    Ang KK; Harris J; Garden AS; Trotti A; Jones CU; Carrascosa L; Cheng JD; Spencer SS; Forastiere A; Weber RS
    J Clin Oncol; 2005 May; 23(13):3008-15. PubMed ID: 15860857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience.
    Robbins KT; Kumar P; Regine WF; Wong FS; Weir AB; Flick P; Kun LE; Palmer R; Murry T; Fontanesi J; Ferguson R; Thomas R; Hartsell W; Paig CU; Salazar G; Norfleet L; Hanchett CB; Harrington V; Niell HB
    Int J Radiat Oncol Biol Phys; 1997 May; 38(2):263-71. PubMed ID: 9226312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative cisplatin and accelerated hyperfractionated radiation induces high tumor response and control rates in patients with advanced head and neck cancer.
    Wanebo HJ; Glicksman AS; Landman C; Slotman G; Doolittle C; Clark J; Koness RJ
    Am J Surg; 1995 Nov; 170(5):512-6. PubMed ID: 7485745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma.
    Nuyts S; Dirix P; Clement PM; Poorten VV; Delaere P; Schoenaers J; Hermans R; Van den Bogaert W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1088-95. PubMed ID: 18707823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
    J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer.
    Newlin HE; Amdur RJ; Riggs CE; Morris CG; Kirwan JM; Mendenhall WM
    Cancer; 2010 Oct; 116(19):4533-40. PubMed ID: 20572028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.
    Huguenin P; Beer KT; Allal A; Rufibach K; Friedli C; Davis JB; Pestalozzi B; Schmid S; Thöni A; Ozsahin M; Bernier J; Töpfer M; Kann R; Meier UR; Thum P; Bieri S; Notter M; Lombriser N; Glanzmann C
    J Clin Oncol; 2004 Dec; 22(23):4665-73. PubMed ID: 15534360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.